Nemes Rush Group LLC Purchases 1,651 Shares of Edwards Lifesciences Co. (NYSE:EW)

Nemes Rush Group LLC increased its holdings in Edwards Lifesciences Co. (NYSE:EW) by 17.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 10,969 shares of the medical research company’s stock after acquiring an additional 1,651 shares during the period. Nemes Rush Group LLC’s holdings in Edwards Lifesciences were worth $1,013,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Crewe Advisors LLC bought a new position in Edwards Lifesciences in the 1st quarter valued at $28,000. First Community Trust NA bought a new position in Edwards Lifesciences during the second quarter valued at about $29,000. Riverview Trust Co purchased a new stake in Edwards Lifesciences during the first quarter worth about $34,000. Webster Bank N. A. bought a new stake in Edwards Lifesciences in the second quarter worth about $39,000. Finally, Rise Advisors LLC boosted its stake in Edwards Lifesciences by 125.0% in the first quarter. Rise Advisors LLC now owns 477 shares of the medical research company’s stock valued at $46,000 after acquiring an additional 265 shares during the last quarter. 79.46% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on EW. Piper Sandler decreased their price target on shares of Edwards Lifesciences from $88.00 to $73.00 and set a “neutral” rating for the company in a research note on Thursday, July 25th. TD Cowen cut Edwards Lifesciences from a “buy” rating to a “hold” rating and dropped their price target for the company from $100.00 to $70.00 in a research report on Thursday, July 25th. Wolfe Research raised Edwards Lifesciences from an “underperform” rating to a “peer perform” rating in a report on Monday, July 29th. Evercore ISI dropped their price objective on shares of Edwards Lifesciences from $91.00 to $76.00 and set an “in-line” rating on the stock in a report on Thursday, July 25th. Finally, Baird R W lowered shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Sixteen investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $79.82.

Insiders Place Their Bets

In other news, VP Daveen Chopra sold 1,250 shares of the stock in a transaction dated Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total transaction of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the completion of the sale, the vice president now owns 29,333 shares of the company’s stock, valued at approximately $2,051,843.35. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Donald E. Bobo, Jr. sold 5,000 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $93.29, for a total transaction of $466,450.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $4,378,659.44. The disclosure for this sale can be found here. Insiders sold a total of 16,250 shares of company stock valued at $1,218,138 over the last 90 days. Insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Up 1.2 %

Shares of NYSE EW opened at $66.58 on Friday. The company has a current ratio of 3.71, a quick ratio of 2.87 and a debt-to-equity ratio of 0.08. The business has a 50-day moving average of $67.78 and a 200-day moving average of $81.96. The firm has a market capitalization of $40.12 billion, a price-to-earnings ratio of 28.70, a PEG ratio of 2.80 and a beta of 1.13. Edwards Lifesciences Co. has a 12 month low of $58.93 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Wednesday, July 24th. The medical research company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business had revenue of $1.63 billion during the quarter, compared to analysts’ expectations of $1.65 billion. During the same quarter in the previous year, the company earned $0.66 EPS. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. Sell-side analysts expect that Edwards Lifesciences Co. will post 2.71 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.